Want to see KRYS full AI Analyst Report?
KRYS Stock Chart & Stats
$356.19
$7.69(2.35%)
At close: 4:00 PM EDT
$356.19
$7.69(2.35%)
Day’s Range― - ―
52-Week Range$136.73 - $382.54
Previous CloseN/A
Volume520.38K
Average Volume (3M)458.39K
Market Cap
$10.64B
Enterprise Value$10.56K
Total Cash (Recent Filing)$845.63M
Total Debt (Recent Filing)$8.85M
Price to Earnings (P/E)44.0
Beta0.62
Next Earnings
Nov 09, 2026EPS Estimate
1.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.27
Shares Outstanding29,598,837
10 Day Avg. Volume221,864
30 Day Avg. Volume458,390
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)5.85
Price to Sales (P/S)18.34
P/FCF Ratio37.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$402.67Price Target Upside13.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)7.62
Revenue Forecast (FY)$501.09M
Bulls Say, Bears Say
Bulls Say
VYJUVEK Commercial GrowthSustained VYJUVEK growth, broad reimbursement approval and penetration beyond the initial target indicate strong patient identification, prescriber adoption and commercial execution in its core rare-disease market.
High Profitability And MarginsRising net income and a 95% gross margin show that the commercial product can generate substantial operating economics. This supports internal investment in the pipeline while reducing dependence on external financing.
Strong Balance Sheet And Cash GenerationHigh cash conversion, substantial liquidity and minimal leverage provide flexibility to fund trials, manufacturing and international expansion. The balance sheet also lowers financing risk if development spending increases.
Bears Say
International Reimbursement UncertaintyPending pricing and reimbursement decisions can delay international patient access and make reported revenue less predictable. Country-specific negotiations and care restrictions may also limit the pace of global VYJUVEK adoption.
Dependence On VYJUVEKThe current revenue base is concentrated in one commercial therapy, so product demand, reimbursement, manufacturing and patient access remain central to results. Pipeline programs must mature successfully to broaden the business model.
Pipeline Execution And Evidence RiskSmall early-stage cohorts provide limited evidence on safety, durability and efficacy, creating risk around registrational decisions and timelines. Delays or weak data could reduce the pipeline’s ability to diversify future growth.
Krystal Biotech News
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $136.73 and its highest was $382.54 in the past 12 months.
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is $10.64B.
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Nov 09, 2026 which is in 67 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on Aug 03, 2026. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.701 by $0.089.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is 1.87.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 29,598,837 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $1.79 in its last earnings report, beating expectations of $1.701. Following the earnings report the stock price went down -8.369%.
Which hedge fund is a major shareholder of Krystal Biotech?
Currently, no hedge funds are holding shares in KRYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Krystal Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$402.67 (13.05% Upside)
$402.67 (13.05% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 80%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 3.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $23.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
146.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.82%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Krystal Biotech
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
KRYS Company Deck
KRYS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial highlights — double‑digit revenue growth (+24% YoY), improved gross margin (95%), expanded U.S. reimbursement (>730 approvals), robust cash (> $1.1B), and advancing clinical programs with several near‑term readouts and encouraging oncology signals. Lowlights were primarily operational and timing risks tied to international pricing/reimbursement (notably a German accrual that depressed reported EMEA revenue), country‑specific access constraints, modest increases in G&A, and the small size/early stage of several repeat‑dose studies. Overall, the positives around revenue, profitability, cash position, and pipeline momentum outweigh the near‑term access and timing headwinds, supporting a constructive outlook.View all KRYS earnings summariesKRYS Stock 12 Month Forecast
Average Price Target
$402.67
▲(13.05% Upside)
Technical Analysis
Ownership Overview
10.99% Insiders
30.30% Mutual Funds
33.61% Other Institutional Investors
2.52% Public Companies and Individual Investors